Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
暂无分享,去创建一个
M. Rezai | P. Fasching | A. Schneeweiss | C. Denkert | H. Tesch | S. Loibl | M. Untch | V. Nekljudova | J. Blohmer | S. Kümmel | G. von Minckwitz | J. Huober | K. Engels | C. Jackisch | C. Hanusch | K. Kast | K. Rhiem | P. Klare | V. Möbus | J. Thomalla | K. Lübbe | M. Frank | B. Ingold‐Heppner